According to a post on the FDA’s website, Pfizer’s treatment of pulmonary arterial hypertension received orphan designation. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Pfizer’s elranatamab receives FDA and EMA filing acceptance
- Pfizer: FDA accepts for review BLA for RSV vaccine candidate
- Pfizer announces TALZENNA, XTANDI combination data from TALAPRO-2 study
- Pfizer announces publication of Phase 3 data for zavegepant in migraine
- Pfizer announces FDA approval of sNDA for CIBINQO